These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Is selecting better than modifying? An investigation of arguments against germline gene editing as compared to preimplantation genetic diagnosis. V Hammerstein AL; Eggel M; Biller-Andorno N BMC Med Ethics; 2019 Nov; 20(1):83. PubMed ID: 31752935 [TBL] [Abstract][Full Text] [Related]
23. Why We Should Defend Gene Editing as Eugenics. Agar N Camb Q Healthc Ethics; 2019 Jan; 28(1):9-19. PubMed ID: 30570459 [TBL] [Abstract][Full Text] [Related]
25. Should germline genome editing be allowed? The effect of treatment characteristics on public acceptability. van Dijke I; van Wely M; Berkman BE; Bredenoord AL; Henneman L; Vliegenthart R; Repping S; Hendriks S Hum Reprod; 2021 Jan; 36(2):465-478. PubMed ID: 33242333 [TBL] [Abstract][Full Text] [Related]
26. Rise of the planet. Jacobs H EMBO Rep; 2013 Jan; 14(1):1. PubMed ID: 23282936 [No Abstract] [Full Text] [Related]
27. Playing it Safe? Precaution, Risk, and Responsibility in Human Genome Editing. Chan S Perspect Biol Med; 2020; 63(1):111-125. PubMed ID: 32063591 [TBL] [Abstract][Full Text] [Related]
28. Gene editing: who should decide? Akabayashi A; Nakazawa E; Caplan AL Nature; 2018 Dec; 564(7735):190. PubMed ID: 30542172 [No Abstract] [Full Text] [Related]
29. Safety of Germline Genome Editing for Genetically Related "Future" Children as Perceived by Parents. Ishii T; Beriain IM CRISPR J; 2019 Dec; 2(6):370-375. PubMed ID: 31746634 [TBL] [Abstract][Full Text] [Related]
30. Who should pay for bad genes? Rakowski E Calif Law Rev; 2002 Oct; 90(5):1345-414. PubMed ID: 12436972 [TBL] [Abstract][Full Text] [Related]
31. Challenging the Boundaries Between Treatment, Prevention, and Enhancement in Human Genome Editing. Waltz M; Walker RL; Flatt MA; MacKay D; Conley JM; Juengst ET; Cadigan RJ CRISPR J; 2024 Aug; 7(4):180-187. PubMed ID: 38976494 [TBL] [Abstract][Full Text] [Related]
32. After the Storm - A Responsible Path for Genome Editing. Daley GQ; Lovell-Badge R; Steffann J N Engl J Med; 2019 Mar; 380(10):897-899. PubMed ID: 30649993 [No Abstract] [Full Text] [Related]
33. Estimating Demand for Germline Genome Editing: An Viotti M; Victor AR; Griffin DK; Groob JS; Brake AJ; Zouves CG; Barnes FL CRISPR J; 2019 Oct; 2(5):304-315. PubMed ID: 31599685 [TBL] [Abstract][Full Text] [Related]
35. Commissions, Consensus, and CRISPR. Barrangou R CRISPR J; 2020 Oct; 3(5):316-317. PubMed ID: 33095046 [No Abstract] [Full Text] [Related]
36. Preimplantation genetic diagnosis: does age of onset matter (anymore)? Krahn T Med Health Care Philos; 2009 Jun; 12(2):187-202. PubMed ID: 18979183 [TBL] [Abstract][Full Text] [Related]
37. The morality and ethics governing CRISPR-Cas9 patents in China. Peng Y Nat Biotechnol; 2016 Jun; 34(6):616-8. PubMed ID: 27281418 [No Abstract] [Full Text] [Related]
38. Procreative Non-Maleficence: A South African Human Rights Perspective on Heritable Human Genome Editing. Thaldar D; Shozi B CRISPR J; 2020 Feb; 3(1):32-36. PubMed ID: 32091250 [TBL] [Abstract][Full Text] [Related]
39. Who's Afraid of the Big Bad (Germline Editing) Wolf? Charo RA Perspect Biol Med; 2020; 63(1):93-100. PubMed ID: 32063589 [TBL] [Abstract][Full Text] [Related]